AGA Clinical Practice Update Provides Expert Guidance on Diagnosing and Managing Cannabinoid Hyperemesis Syndrome
The American Gastroenterological Association issued its first clinical practice update on cannabinoid hyperemesis syndrome, providing expert-reviewed guidance on diagnosis and management of this increasingly common condition.
Quick Facts
What This Study Found
The AGA Clinical Practice Update provides consensus expert guidance on recognizing, diagnosing, and treating CHS, a condition characterized by cyclic nausea, vomiting, and compulsive hot water bathing in the setting of chronic cannabis use. The update underwent internal and external peer review.
Key Numbers
First AGA clinical practice update on CHS; peer-reviewed by CPUC and approved by AGA Governing Board.
How They Did This
Expert commentary commissioned by the AGA Clinical Practice Updates Committee, incorporating published evidence and author experience, with internal and external peer review.
Why This Research Matters
CHS is increasingly common with rising cannabis use but remains underdiagnosed. Having the AGA, the leading US gastroenterology organization, publish formal guidance legitimizes the condition and gives clinicians a reference standard for diagnosis and management.
The Bigger Picture
As cannabis use increases, emergency departments and gastroenterologists are seeing more CHS cases. Official professional society guidance helps standardize care and may reduce the diagnostic delays that characterize this condition.
What This Study Doesn't Tell Us
Expert commentary rather than systematic review. Based on limited published evidence. Author experience may not represent all clinical settings.
Questions This Raises
- ?Will this guidance reduce the average time to CHS diagnosis?
- ?Are the recommended treatments supported by randomized controlled trials?
Trust & Context
- Key Stat:
- First AGA clinical practice update on CHS
- Evidence Grade:
- AGA-commissioned expert commentary with peer review, representing professional consensus rather than systematic evidence review.
- Study Age:
- 2024 publication
- Original Title:
- AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary.
- Published In:
- Gastroenterology, 166(5), 930-934.e1 (2024)
- Authors:
- Rubio-Tapia, Alberto, McCallum, Richard(2), Camilleri, Michael(2)
- Database ID:
- RTHC-05671
Evidence Hierarchy
Frequently Asked Questions
What is cannabinoid hyperemesis syndrome?
CHS is a condition in chronic cannabis users characterized by cyclic nausea, vomiting, and compulsive hot water bathing. The AGA has now issued formal clinical guidance on its diagnosis and management.
How is CHS diagnosed and treated?
The AGA clinical practice update provides expert-reviewed guidance on recognizing CHS, distinguishing it from other conditions, and managing it. The full guidance was published in Gastroenterology in 2024.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBD-oil-quality-guide
- CBT-cannabis-recovery
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cannabis-relapse-cycle-pattern
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- medical-benefits-of-cannabis
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-before-surgery
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- seniors-older-adults-cannabis-risks-medications
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-breastfeeding-THC-breast-milk
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-05671APA
Rubio-Tapia, Alberto; McCallum, Richard; Camilleri, Michael. (2024). AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary.. Gastroenterology, 166(5), 930-934.e1. https://doi.org/10.1053/j.gastro.2024.01.040
MLA
Rubio-Tapia, Alberto, et al. "AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary.." Gastroenterology, 2024. https://doi.org/10.1053/j.gastro.2024.01.040
RethinkTHC
RethinkTHC Research Database. "AGA Clinical Practice Update on Diagnosis and Management of ..." RTHC-05671. Retrieved from https://rethinkthc.com/research/rubio-tapia-2024-aga-clinical-practice-update
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.